| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Financial Outlook
For full-year 2024, Clover Health is providing its guidance as follows:
| Guidance | |
| Insurance revenue | $1.25 billion - $1.30 billion |
| Insurance MCR | 79% - 83% |
| Adjusted SG&A (Non-GAAP)(1) | $270 million - $280 million |
| Adjusted EBITDA (Non-GAAP)(1) | ($20) million - $20 million |
(1) Reconciliations of projected Adjusted SG&A (non-GAAP) to projected SG&A, and projected Adjusted EBITDA (non-GAAP) to Net loss, the most directly comparable GAAP measures, are not provided because Stock-based compensation expense, which is excluded from Adjusted SG&A (non-GAAP) and Adjusted EBITDA (non-GAAP), cannot be reasonably calculated or predicted at this time without unreasonable efforts. Additional information about the Company's non-GAAP financial measures can be found under the caption "About Non-GAAP Financial Measures" below and in Appendix A.
Posted In: CLOV
